CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it has granted equity awards to 26 newly hired non-executive employees as part of its 2025 Inducement Plan. The awards, approved by the company’s independent Compensation Committee, were issued on August 1 in line with Nasdaq Listing Rule 5635(c)(4).
The new hires received stock options for a total of 1,984 shares at an exercise price of $302.17, matching the closing price on the grant date. Additionally, they were awarded 9,727 restricted stock units. Option grants vest over four years, beginning with 25% on the first anniversary and the remainder quarterly thereafter. RSUs will vest in equal annual installments over the same period, contingent on continued employment.
Madrigal is focused on treating metabolic dysfunction-associated steatohepatitis (MASH). Its lead product, Rezdiffra, is the first FDA-approved treatment for MASH with moderate to advanced fibrosis and is currently being evaluated in a Phase 3 trial for MASH cirrhosis.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.